Exclusive Summary

• An NDA-stage Dry Powder Inhaler (DPI) directly targeting the $2.6 billion Symbicort Turbuhaler market, fully de-risked with successfully matched PK bioequivalence and robust Phase III clinical outcomes.
• Features highly differentiated, self-developed device IP equipped with a precise 2-dose scale counter and dual-click auditory feedback, significantly improving patient compliance compared to existing competitors on the market.
• Manufacturing is commercialization-ready, targeting the massive $46.8 billion global asthma/COPD space with highly mapped revenue potential in emerging markets including LATAM, Southeast Asia, Oceania, and MENA.
• Extremely low development risk with high commercial readiness, representing a premium asset for overseas pharmaceutical companies seeking out-licensing, exclusive regional distribution, or immediate portfolio expansion in respiratory care.

Asset Materials

Contact Us for Full Materials